0001209191-23-036127.txt : 20230609 0001209191-23-036127.hdr.sgml : 20230609 20230609211639 ACCESSION NUMBER: 0001209191-23-036127 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230608 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leheny A. Rachel CENTRAL INDEX KEY: 0001484729 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39538 FILM NUMBER: 231006937 MAIL ADDRESS: STREET 1: C/O ANTHERA PHARMACEUTICALS, INC. STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CalciMedica, Inc. CENTRAL INDEX KEY: 0001534133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452120079 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-952-5500 MAIL ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: CalciMedica, Inc. /DE/ DATE OF NAME CHANGE: 20230322 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG VISION, INC. DATE OF NAME CHANGE: 20170717 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG, Inc. DATE OF NAME CHANGE: 20150303 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-08 0 0001534133 CalciMedica, Inc. CALC 0001484729 Leheny A. Rachel C/O CALCIMEDICA, INC. 505 COAST S. BLVD. #202 LA JOLLA CA 92037 1 1 1 0 Chief Executive Officer 0 Common Stock 2023-06-08 4 P 0 928 5.2269 A 8928 D Common Stock 2023-06-09 4 P 0 400 5.25 A 9328 D Common Stock 1000 I By Spouse Common Stock 356989 I By Valence Investments SPV IV, LLC Common Stock 66228 I By Valence Investments SPV V, LLC Common Stock 316109 I By Valence Investments SPV VI, LLC The weighted average purchase price for the transaction reported was $5.2269, and the range of prices were between $5.20 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein. By John Dunn, Attorney-in-Fact 2023-06-09